<SEC-DOCUMENT>0001193125-21-109109.txt : 20210408
<SEC-HEADER>0001193125-21-109109.hdr.sgml : 20210408
<ACCEPTANCE-DATETIME>20210407185307
ACCESSION NUMBER:		0001193125-21-109109
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210407
FILED AS OF DATE:		20210408
DATE AS OF CHANGE:		20210407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		21813398

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d112417d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated April&nbsp;7, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d112417dex991.htm">IMMUTEP ANNOUNCES EUROPEAN PATENT GRANT FOR LAG525 ANTIBODY IN COMBINATION THERAPY </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: April 7, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d112417dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g112417g31l01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX/Media Release </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP ANNOUNCES EUROPEAN PATENT GRANT FOR </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LAG525 ANTIBODY IN COMBINATION THERAPY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; </B><B>7</B><B></B><B>&nbsp;April 2021 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#147; or
&#147;the Company&#147;), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, is pleased to announce the grant of patent number<B> </B>EP3317301<B> </B>entitled &#147;Combination
therapies comprising antibody molecules to <FONT STYLE="white-space:nowrap">LAG-3&#148;</FONT> by the European Patent Office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The claims of EP3317301 are
directed to embodiments of LAG525, a humanised form of Immutep&#146;s IMP701 antibody which is <FONT STYLE="white-space:nowrap">out-licensed</FONT> to Novartis AG. In particular, the claims of the patent are directed to compositions comprising
LAG525 and spartalizumab, an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody molecule, and related methods of use of the combination in the treatment of cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent is <FONT STYLE="white-space:nowrap">co-owned</FONT> by Novartis AG and Immutep S.A.S. and will expire on 28&nbsp;July 2036. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IMP701 and LAG525 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP701 is a therapeutic antibody
originally developed by Immutep S.A. (now Immutep S.A.S.) to target <FONT STYLE="white-space:nowrap">LAG-3.</FONT> This antagonist antibody plays a role in controlling the signalling pathways in both effector T cells and regulatory T cells (Treg).
The antibody works to both activate effector T cells (by blocking inhibitory signals that would otherwise switch them off) and at the same time inhibit Treg function that normally prevents T cells from responding to antigen stimulation. The antibody
therefore removes two brakes that prevent the immune system from responding to and killing cancer cells. In contrast, some other checkpoint antibodies in development target only the effector T cell pathway. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rights to the development and commercialisation of IMP701 are exclusively licensed to Novartis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LAG525, a humanised form of IMP701 is being evaluated by Novartis in several Phase I and/or Phase II clinical trials in combination with Novartis&#146; <FONT
STYLE="white-space:nowrap">PD-1</FONT> inhibitor spartalizumab for the treatment of certain cancer(s). Novartis has full responsibility for the continued development of the <FONT STYLE="white-space:nowrap">LAG-3</FONT> antibody program and Immutep
is eligible to receive development-based milestone payments and sales-based royalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information on the clinical studies may be obtained at:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>https://clinicaltrials.gov/ct2/show/NCT03365791 </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>https://clinicaltrials.gov/ct2/show/NCT03499899 </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>https://clinicaltrials.gov/ct2/show/NCT02460224 </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>https://clinicaltrials.gov/ct2/show/NCT03742349 </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>https://clinicaltrials.gov/ct2/show/NCT03484923 </U></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology company that is a leader in the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT>
related immunotherapeutic products for the treatment of cancer, infectious disease and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize
value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g112417g31l01.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;),
a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting
cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT>
products, including antibodies for immune response modulation, are being developed by Immutep&#146;s large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information
can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim
McCarthy, LifeSci Advisors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) 915.2564;&nbsp;<U>tim@lifesciadvisors.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g112417g31l01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g112417g31l01.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
MK-J%G'=K:-=1+<MTB+C<?PH LT % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!Q'C&>XM=8LYX7*%(\HP[')S_2L*C::.#$MQFFC7\*SP3Z4
M9FV?:"Y\YL $G/&?PJZ;31OAVG"_4Y'Q!'G4[B>'#6K/M1E.5R ,@5C/>YQ5
ME[S:V._T3>-$LM_WO)7K]*Z([(]&E\"+]4:!0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * //=1
MNKA?%[1K/($^T(-H<X[=JYVWSGFSD_;6OU-OQG=7%M9VWD3/%N<AMC$9XJZC
M:6AOB9.,59G/V/A[4]5M%O$G38V<;W.>#CTK-0;5SGA1G-<R97&H:OI<DM@+
MF2-L[2I;.#[$]*5Y1T)YZD'RW+T_A?6A"UT\JNX&XKYA+_Y_&JY);FCH5+7+
MWA#6KB6Z-A<R-(I4F-F.2".V:JG)[,O#56WRL?XUN[FWDM$AGDC5E;<$8C/2
MBHVAXJ35K,S(O"VK7%HEVDL;;T#J/,.X@C/I4*$FKF2H5&N:Y4MM1UF8KID5
MU(&9MH!;!!],]:2E+8B,ZC]Q,L7WA[5M-MS>/*&"\L8Y#N7WIN$EJ5*C4@N8
MZ'PCK$U_!+;W+EY8<$,>I4^M:4Y7T9TX>HYJSZ''^/+VZ@\3R)#<S1IY2?*C
MD#I6IU'J4?\ J4_W10!Y7H][=OX^2)KJ8Q_:G&PN<8Y[4 :OQ0Z:5_VU_P#9
M: ,;2_#'B*]TV"YL[K9;R#*+Y[+CGTH ]"\-65YI>B+!J,H>=69F;>6XSZF@
M#@]5U_5?%.L?V?I;NEN6*HB-MW =68^E $&H>&M=\,0+J"70VJ1O>!SE?KTX
MH [KPAK[:[I):?'VJ!MDF.-WH?Q_I0!YU(^JZYXA?3UO96=YG5!)*VT8S_04
M 7KOP?XBT:!KR&<.(QN8V\K;@/7M0!T?@GQ9-JDATZ_8-<*NZ.3H7 Z@^] '
M;4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YQJ?_(YM_P!?"?TKFE\9
MYD_XWS-KQU_QYV?^^W\JNKLC?%_"C2\)?\BY;_5O_0C5T_A-</\ PT<IXP_Y
M&&7_ '%_E6-3XCCQ/\0]$7[@^E=)Z9YUX?\ ^1MB_P"NC_R-<T/B/,H_Q31\
M=_Z^R_W6_F*JKNC3%[HZK2?^0/9?]<$_]!%:QV1V4_@1P9_Y'?\ [??_ &:L
M/MGG?\O_ )G>ZG_R";S_ *XO_(UO+9GHS^!G&^!_^0K/_P!<?_9A65+<X<)\
M3*GQ(TJ47D&J1H3"R".0C^$@G!/US^E;GHDNE_$>&WTZ&"\LY7FB0+OC(PV.
M_/2@#GO#DXN?'-M. 5$MPS@'MG)H Z_XD:?+<:3;7<:EA;.=^.RMCG\P* ,;
MPWXZ@TC2([&ZM99/*)V-&1R"<X.?K0!V>BZQ!XITBX?R#$A9H60MDXQ_]>@#
MS93J/@CQ$6,>=N5&>%E0^_Y?0T =6/B;8^5DZ?/YG]W<N/S_ /K4 =)X?UE=
M=TI;T1>42[*4W9Q@^OTQ0!Y-;ZD=(\4M?",2>3.YV$XSR1U_&@#KKWXEQ-9N
MMG8R+<,,!I&&U3Z\=: *'P_T:>YU7^UID800YV,W\;GC],F@#T^@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MK#(/#=J /21X5T(2^8-+@W?[O'Y=* -9$2-%1%"(HP%48 H =0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0! +*U6X,XMX
MA,3G>$&[/UH ?Y$7EK'Y:[%((7;P"#D'\Z &265K+*)9+>)Y!CYF0$\=* )7
MC26,QR*'0C!!&0: &PP16Z%(8DC7.<*,#- "M#&V_=&IWKM;(^\.>#[<G\Z
M%>-)$V.H9?0CB@ 6-$9BJ@%CEB!U.,?T% #6MX6C>-HD*/RRE1@_6@!J6EO'
M"\*01K$^=R!0 <]<B@!YC0R*Y4%U! ;'(!Z_R% $9LK4S^>;:(RYSOV#.?7-
M $I12RL5!*]#CI0 AAC(D!1?WGW^/O<8Y]>* (YK*UN"AFMXI"@PNY <#VH
MD6*-2I5%!5=H('0>E ")!%'MV1HNP;5PN,#T'Y"@ \B+)/EKDMO/'\7K]: '
M.BR(R.H96&"",@B@!<8&!P* *<6D:;!<"XBL+9)P21(L2AL^N<4 7: "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H \T_X2O6?^?O_ ,AK_A7+[21Y?UBIW#_A*]9_Y^__ "&O^%'M)!]8
MJ=P_X2O6?^?O_P AK_A1[20?6*G</^$KUG_G[_\ (:_X4>TD'UBIW#_A*]9_
MY^__ "&O^%'M)!]8J=P_X2O6?^?O_P AK_A1[20?6*G</^$KUG_G[_\ (:_X
M4>TD'UBIW#_A*]9_Y^__ "&O^%'M)!]8J=P_X2O6?^?O_P AK_A1[20?6*G<
M/^$KUG_G[_\ (:_X4>TD'UBIW#_A*]9_Y^__ "&O^%'M)!]8J=P_X2O6?^?O
M_P AK_A1[20?6*G</^$KUG_G[_\ (:_X4>TD'UBIW#_A*]9_Y^__ "&O^%'M
M)!]8J=P_X2O6?^?O_P AK_A1[20?6*G</^$KUG_G[_\ (:_X4>TD'UBIW#_A
M*]9_Y^__ "&O^%'M)!]8J=P_X2O6?^?O_P AK_A1[20?6*G</^$KUG_G[_\
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M*]9_Y^__ "&O^%'M)!]8J=P_X2O6?^?O_P AK_A1[20?6*G</^$KUG_G[_\
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8^Q19!RQ[!]@L_P#GT@_[]BBR#ECV/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
